ARCHIVES

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

November 27, 1998

Journal Editors Were Unaware Of Tobacco Funding.

March 28, 2008

ASCO Study Predicts Shortage of Oncologists.

March 23, 2007

In Brief” McKenna New ACS President, Lemaistre President Elect; Michael Potter Wins Albert Lasker Award

November 23, 1984

DCCP Board Approves Concepts For Nearly $20 Million In Grants, Contracts, Including New Inhibitors Study

June 10, 1983

DCT Board Approves Continuing Neutron Trials Pas 1989 Expiration, With New Funding Plan

June 10, 1988